Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 4Neoplasms 2Solid Tumors 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 2a 1Lymphoma, Large-Cell, Anaplastic 1Lung Diseases 1Genomic Instability 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bone Neoplasms 1Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 36Bevacizumab 25Cyclophosphamide 23Blood Specimen Collection 19Nivolumab 17Standard of Care 15Carboplatin 15Paclitaxel 14atezolizumab 13Gemcitabine 13Exercise 13Pemetrexed 11Fluorouracil 11Doxorubicin 11Cisplatin 11Cetuximab 10Radiotherapy 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9130-nm albumin-bound paclitaxel 9durvalumab 8abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Rituximab 8Prednisone 8Biopsy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × alectinib × 90 days × Clear all
NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Hoffmann-La Roche

Phase 3 Active not recruiting
200 enrolled
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡